NeuroSense Therapeutics Ltd
NRSN
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.47M
Close$
$-0.00
100.1% downside
Current Fair Value
100.1% downsideOvervalued by 100.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.47 Million |
|---|---|
| Enterprise Value | $6.47 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.8 |
| Beta | 1.64 |
| Outstanding Shares | 1,278,000 |
Return
| Return on Equity | 713.14% |
|---|---|
| Return on Assets | -1082.20% |
| Return on Invested Capital | 744.96% |
Valuation & Multiples
| P/E Ratio | -0.52 |
|---|---|
| PEG | -0.66 |
| Price to Sales | - |
| Price to Book Ratio | -1.54 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 25, 2026
EPS Estimate
$-3.90
Average shareholder expectationRevenue Estimate
$535,600
Average shareholder expectationNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-0.79
Average shareholder expectationRevenue Estimate
$535,600
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.56%▲ 0.07% |
|---|---|
| Total Invested | $285,749▼ 0.32% |
| Investors Holding | 12▼ 1.00% |
ESG Score
No data